Displaying drugs 15051 - 15075 of 15720 in total
N-Octyl-2-Hydroxyethyl Sulfoxide
Experimental
XL765
XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.
Investigational
Matched Description: … shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and …
IDM-2
IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Investigational
Matched Description: … from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and …
2-Cyclopropylmethylenepropanal
Experimental
AZD-8186
AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery).
Investigational
Matched Description: … AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel …
BMS-986104
BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).
Investigational
Matched Description: … Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and …
K-00546
Experimental
PKI-179
PKI-179 has been used in trials studying the treatment of Advanced Malignant Solid Tumors.
Investigational
Neocitrullamon
Experimental
Fluorofuranylnorprogesterone F-18
Fluorofuranylnorprogesterone F-18 is under investigation in clinical trial NCT02455453 (Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography).
Investigational
Matched Iupac: … (1R,2S,4R,6R,8S,9S,12S,13R)-8-[2-(¹⁸F)fluoroacetyl]-6-(furan-2-yl)-9-methyl-5,7-dioxapentacyclo[10.8.0.0 …
Lobeline
An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]
Investigational
Matched Description: … variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and …
Phenylacetaldehyde
Experimental
N-[2-hydroxy-1-indanyl]-5-[(2-tertiarybutylaminocarbonyl)-4(benzo[1,3]dioxol-5-ylmethyl)-piperazino]-4-hydroxy-2-(1-phenylethyl)-pentanamide
Experimental
Matched Iupac: … (2S)-4-[(2H-1,3-benzodioxol-5-yl)methyl]-N-tert-butyl-1-[(2S,4R)-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3- …
Dimethyl Propionate Ester Heme
Experimental
Matched Iupac: … methyl 3-[(1R)-9,14-diethenyl-20-(3-methoxy-3-oxopropyl)-5,10,15,19-tetramethyl-2,22,23,25-tetraaza-1 …
beta-Apopicropodophyllin
beta-Apopicropodophyllin is a component of the freshwater plant Micranthemum umbrosum.
Experimental
ONT-093
ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.
Investigational
Matched Description: … In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations …
2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid
Experimental
(R)-Atenolol
Experimental
Displaying drugs 15051 - 15075 of 15720 in total